{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:53:26Z","timestamp":1781646806173,"version":"3.54.5"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","award":["98-3-14-16152"],"award-info":[{"award-number":["98-3-14-16152"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Various forms of cancer immunotherapy are promising in overcoming the obstacles posed by resistance to conventional chemo- and radiotherapy. Cancer vaccines could serve as beneficial adjuncts to conventional therapies, offering the potential for fine-tuning to reduce relapse and related mortality. Continuing prior investigations, a therapeutic colorectal cancer stem cell (CSC)-based vaccine was developed to explore whether this vaccination could inhibit the formation and prolong survival rates in a mouse model of colorectal cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      CSCs were enriched from the CT-26 cell line using sphere formation assay and characterized by real-time q-PCR for stemness genes (\n                      <jats:italic>Oct4<\/jats:italic>\n                      ,\n                      <jats:italic>Sox2<\/jats:italic>\n                      , and\n                      <jats:italic>Nanog<\/jats:italic>\n                      ) and tumorigenesis assay in syngeneic BALB\/c mice. Different groups of mice were intraperitoneally immunized with the CSC lysate-based vaccine, the parental cell lysate-based vaccine, and control groups following subcutaneous challenge with CT-26 cells. Beyond analyzing tumor growth and survival rates, histological analysis of tumor tissues was conducted using comprehensive hematoxylin and eosin (H&amp;E) staining, and antibody responses in vaccinated mice were evaluated by flow cytometry and immunofluorescence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Immunization of tumor-bearing mice with the CT-26 CSC lysate-based vaccine caused delayed tumor formation, reduced tumor growth rate, and enhanced survival rate compared to the control groups. The histological responses observed in the lysate vaccination subgroups indicated a potent immune response. Furthermore, flow cytometry and immunofluorescence analyses demonstrated the production of anti-CSC and anti-parental cell antibodies in mice immunized with CT-26 CSC and parental cell lysates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest that targeting CSCs using a CSC lysate-based vaccine can stimulate cellular and humoral immunity and represent a novel therapeutic approach to complement conventional antitumor therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15925-3","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T02:04:37Z","timestamp":1774749877000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic efficacy of cancer stem cell-based vaccine in colorectal murine model: reduced tumor growth and prolonged survival"],"prefix":"10.1186","volume":"26","author":[{"given":"Farideh","family":"Hashemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoumeh","family":"Dehghan Manshadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadegh","family":"Safaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Aminianfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Bozorgmehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Eini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Shariftabrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdieh","family":"Razmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh","family":"Naseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roya","family":"Ghods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Madjd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,29]]},"reference":[{"issue":"3","key":"15925_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"issue":"4","key":"15925_CR2","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.3390\/ijms22041603","volume":"22","author":"A Angius","year":"2021","unstructured":"Angius A, Scanu AM, Arru C, Muroni MR, Rallo V, Deiana G, et al. Portrait of cancer stem cells on colorectal cancer: Molecular biomarkers, signaling pathways and mirnaome. Int J Mol Sci. 2021;22(4):1603.","journal-title":"Int J Mol Sci"},{"key":"15925_CR3","doi-asserted-by":"crossref","unstructured":"Scanu AM, De Miglio MR. Therapeutic Landscapes in Colorectal Carcinoma. MDPI; 2023. p. 821.","DOI":"10.3390\/books978-3-0365-9440-8"},{"issue":"6","key":"15925_CR4","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3390\/pharmaceutics14061213","volume":"14","author":"N Krasteva","year":"2022","unstructured":"Krasteva N, Georgieva M. Promising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials. Pharmaceutics. 2022;14(6):1213.","journal-title":"Pharmaceutics"},{"issue":"s1","key":"15925_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3747\/co.26.5575","volume":"26","author":"A Parmar","year":"2019","unstructured":"Parmar A, Chan K, Ko Y. Metastatic colorectal cancer: therapeutic options for treating refractory disease. Curr Oncol. 2019;26(s1):24\u201332.","journal-title":"Curr Oncol"},{"issue":"2","key":"15925_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2217\/pme-2020-0099","volume":"18","author":"A Zalewski","year":"2021","unstructured":"Zalewski A, Snook AE, Waldman SA. Stem cells as therapeutic targets in colorectal cancer. Personalized Med. 2021;18(2):171\u201383.","journal-title":"Personalized Med"},{"issue":"2","key":"15925_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.pharmthera.2013.01.014","volume":"138","author":"Y Shiozawa","year":"2013","unstructured":"Shiozawa Y, Nie B, Pienta KJ, Morgan TM, Taichman RS. Cancer stem cells and their role in metastasis. Pharmacol Ther. 2013;138(2):285\u201393.","journal-title":"Pharmacol Ther"},{"key":"15925_CR8","doi-asserted-by":"crossref","unstructured":"Ghadially R, Kim RW, Charruyer-Reinwald A. Cancer Stem Cells and Their Role in Metastasis. Cancer Metastasis Through the Lymphovascular System. Springer; 2022. pp. 749\u201356.","DOI":"10.1007\/978-3-030-93084-4_71"},{"issue":"3","key":"15925_CR9","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.3390\/ijms24032555","volume":"24","author":"L Liang","year":"2023","unstructured":"Liang L, Kaufmann AM. The Significance of Cancer Stem Cells and Epithelial\u2013Mesenchymal Transition in Metastasis and Anti-Cancer Therapy. Int J Mol Sci. 2023;24(3):2555.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"15925_CR10","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3390\/cancers13030376","volume":"13","author":"M Marzagalli","year":"2021","unstructured":"Marzagalli M, Fontana F, Raimondi M, Limonta P. Cancer stem cells\u2014Key players in tumor relapse. Cancers. 2021;13(3):376.","journal-title":"Cancers"},{"key":"15925_CR11","doi-asserted-by":"crossref","unstructured":"Chen L, Yang F, Chen S, Tai J. Mechanisms on chemotherapy resistance of colorectal cancer stem cells and research progress of reverse transformation: A mini-review. Front Med. 2022;9.","DOI":"10.3389\/fmed.2022.995882"},{"issue":"1","key":"15925_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/sctm.18-0123","volume":"8","author":"A Desai","year":"2019","unstructured":"Desai A, Yan Y, Gerson SL. Concise reviews: cancer stem cell targeted therapies: toward clinical success. Stem Cells Translational Med. 2019;8(1):75\u201381.","journal-title":"Stem Cells Translational Med"},{"issue":"1","key":"15925_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-022-02904-1","volume":"13","author":"F Ju","year":"2022","unstructured":"Ju F, Atyah MM, Horstmann N, Gul S, Vago R, Bruns CJ, et al. Characteristics of the cancer stem cell niche and therapeutic strategies. Stem Cell Res Ther. 2022;13(1):1\u201317.","journal-title":"Stem Cell Res Ther"},{"key":"15925_CR14","doi-asserted-by":"crossref","unstructured":"Phi LTH, Sari IN, Yang Y-G, Lee S-H, Jun N, Kim KS et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem cells international. 2018;2018.","DOI":"10.1155\/2018\/5416923"},{"issue":"4","key":"15925_CR15","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3390\/cancers14040976","volume":"14","author":"B Aramini","year":"2022","unstructured":"Aramini B, Masciale V, Grisendi G, Bertolini F, Maur M, Guaitoli G, et al. Dissecting tumor growth: The role of cancer stem cells in drug resistance and recurrence. Cancers. 2022;14(4):976.","journal-title":"Cancers"},{"issue":"2","key":"15925_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3390\/cancers13020328","volume":"13","author":"V Castelli","year":"2021","unstructured":"Castelli V, Giordano A, Benedetti E, Giansanti F, Quintiliani M, Cimini A, et al. The great escape: the power of cancer stem cells to evade programmed cell death. Cancers. 2021;13(2):328.","journal-title":"Cancers"},{"key":"15925_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fgene.2020.00312","volume":"11","author":"RY Alhabbab","year":"2020","unstructured":"Alhabbab RY. Targeting cancer stem cells by genetically engineered chimeric antigen receptor T cells. Front Genet. 2020;11:312.","journal-title":"Front Genet"},{"issue":"5","key":"15925_CR18","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3390\/cancers15051608","volume":"15","author":"AS K\u00f6seer","year":"2023","unstructured":"K\u00f6seer AS, Di Gaetano S, Arndt C, Bachmann M, Dubrovska A. Immunotargeting of cancer stem cells. Cancers. 2023;15(5):1608.","journal-title":"Cancers"},{"issue":"1","key":"15925_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target therapy. 2020;5(1):8.","journal-title":"Signal Transduct Target therapy"},{"key":"15925_CR20","doi-asserted-by":"publisher","first-page":"113906","DOI":"10.1016\/j.biopha.2022.113906","volume":"156","author":"E Rouzbahani","year":"2022","unstructured":"Rouzbahani E, Majidpoor J, Najafi S, Mortezaee K. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. Biomed Pharmacother. 2022;156:113906.","journal-title":"Biomed Pharmacother"},{"issue":"21","key":"15925_CR21","doi-asserted-by":"publisher","first-page":"9891","DOI":"10.1111\/jcmm.16939","volume":"25","author":"X Cui","year":"2021","unstructured":"Cui X, Liu R, Duan L, Cao D, Zhang Q, Zhang A. CAR-T therapy: Prospects in targeting cancer stem cells. J Cell Mol Med. 2021;25(21):9891\u2013904.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"15925_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/stmcls\/sxac089","volume":"41","author":"F Hashemi","year":"2023","unstructured":"Hashemi F, Razmi M, Tajik F, Z\u00f6ller M, Dehghan Manshadi M, Mahdavinezhad F, et al. Efficacy of whole cancer stem cell-based vaccines: A systematic review of preclinical and clinical studies. Stem Cells. 2023;41(3):207\u201332.","journal-title":"Stem Cells"},{"key":"15925_CR23","doi-asserted-by":"crossref","unstructured":"Huang B, Miao L, Liu J, Zhang J, Li Y. A promising antitumor method: Targeting CSC with immune cells modified with CAR. Front Immunol. 2022;13.","DOI":"10.3389\/fimmu.2022.937327"},{"key":"15925_CR24","doi-asserted-by":"publisher","first-page":"105861","DOI":"10.1016\/j.biocel.2020.105861","volume":"129","author":"E Quaglino","year":"2020","unstructured":"Quaglino E, Cavallo F, Conti L. Cancer stem cell antigens as targets for new combined anti-cancer therapies. Int J Biochem Cell Biol. 2020;129:105861.","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"15925_CR25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/stem.1292","volume":"31","author":"S Duarte","year":"2013","unstructured":"Duarte S, Momier D, Baqu\u00e9 P, Casanova V, Loubat A, Samson M, et al. Preventive cancer stem cell-based vaccination reduces liver metastasis development in a rat colon carcinoma syngeneic model. Stem Cells. 2013;31(3):423\u201332.","journal-title":"Stem Cells"},{"key":"15925_CR26","doi-asserted-by":"crossref","unstructured":"Zheng F, Dang J, Zhang H, Xu F, Ba D, Zhang B et al. Cancer stem cell vaccination with PD-L1 and CTLA-4 blockades enhances the eradication of melanoma stem cells in a mouse tumor model. Journal of immunotherapy (Hagerstown, Md: 1997). 2018;41(8):361.","DOI":"10.1097\/CJI.0000000000000242"},{"key":"15925_CR27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.bioactmat.2022.10.016","volume":"22","author":"X Zhang","year":"2023","unstructured":"Zhang X, Cui H, Zhang W, Li Z, Gao J. Engineered tumor cell-derived vaccines against cancer: The art of combating poison with poison. Bioactive Mater. 2023;22:491\u2013517.","journal-title":"Bioactive Mater"},{"key":"15925_CR28","doi-asserted-by":"publisher","first-page":"114547","DOI":"10.1016\/j.biopha.2023.114547","volume":"161","author":"H Xu","year":"2023","unstructured":"Xu H, Zhao F, Wu D, Zhang Y, Bao X, Shi F, et al. Eliciting effective tumor immunity against ovarian cancer by cancer stem cell vaccination. Biomed Pharmacother. 2023;161:114547.","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"15925_CR29","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1158\/0008-5472.CAN-11-1400","volume":"72","author":"N Ning","year":"2012","unstructured":"Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Yet J, et al. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res. 2012;72(7):1853\u201364.","journal-title":"Cancer Res"},{"key":"15925_CR30","doi-asserted-by":"crossref","unstructured":"Eini L, Naseri M, Karimi-Busheri F, Bozorgmehr M, Ghods R, Madjd Z. Preventive cancer stem cell-based vaccination modulates tumor development in syngeneic colon adenocarcinoma murine model. J Cancer Res Clin Oncol. 2022:1\u201316.","DOI":"10.1007\/s00432-022-04303-8"},{"key":"15925_CR31","doi-asserted-by":"crossref","unstructured":"Sela M, Hilleman MR. Therapeutic vaccines: realities of today and hopes for tomorrow. National Acad Sciences; 2004. p. 14559.","DOI":"10.1073\/pnas.0405924101"},{"issue":"9","key":"15925_CR32","doi-asserted-by":"publisher","first-page":"e1211218","DOI":"10.1080\/2162402X.2016.1211218","volume":"5","author":"L Wang","year":"2016","unstructured":"Wang L, Ma N, Okamoto S, Amaishi Y, Sato E, Seo N, et al. Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. Oncoimmunology. 2016;5(9):e1211218.","journal-title":"Oncoimmunology"},{"issue":"8","key":"15925_CR33","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1128\/jcm.27.8.1893-1895.1989","volume":"27","author":"B Cahoon-Young","year":"1989","unstructured":"Cahoon-Young B, Chandler A, Livermore T, Gaudino J, Benjamin R. Sensitivity and specificity of pooled versus individual sera in a human immunodeficiency virus antibody prevalence study. J Clin Microbiol. 1989;27(8):1893\u20135.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"15925_CR34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41392-021-00499-2","volume":"6","author":"C Su","year":"2021","unstructured":"Su C, Zhang J, Yarden Y, Fu L. The key roles of cancer stem cell-derived extracellular vesicles. Signal Transduct Target Therapy. 2021;6(1):109.","journal-title":"Signal Transduct Target Therapy"},{"issue":"2","key":"15925_CR35","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3390\/ijms24021786","volume":"24","author":"RA Eid","year":"2023","unstructured":"Eid RA, Alaa Edeen M, Shedid EM, Kamal ASS, Warda MM, Mamdouh F, et al. Targeting Cancer Stem Cells as the Key Driver of Carcinogenesis and Therapeutic Resistance. Int J Mol Sci. 2023;24(2):1786.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"15925_CR36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41392-020-00430-1","volume":"6","author":"H-M Zhou","year":"2021","unstructured":"Zhou H-M, Zhang J-G, Zhang X, Li Q. Targeting cancer stem cells for reversing therapy resistance: Mechanism, signaling, and prospective agents. Signal Transduct Target therapy. 2021;6(1):62.","journal-title":"Signal Transduct Target therapy"},{"key":"15925_CR37","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.molimm.2019.04.001","volume":"111","author":"NE El-Ashmawy","year":"2019","unstructured":"El-Ashmawy NE, El-Zamarany EA, Salem ML, Khedr EG, Ibrahim AO. A new strategy for enhancing antitumor immune response using dendritic cells loaded with chemo-resistant cancer stem-like cells in experimental mice model. Mol Immunol. 2019;111:106\u201317.","journal-title":"Mol Immunol"},{"issue":"3","key":"15925_CR38","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3390\/cells10030543","volume":"10","author":"C Donini","year":"2021","unstructured":"Donini C, Rotolo R, Proment A, Aglietta M, Sangiolo D, Leuci V. Cellular immunotherapy targeting cancer stem cells: preclinical evidence and clinical perspective. Cells. 2021;10(3):543.","journal-title":"Cells"},{"issue":"12","key":"15925_CR39","doi-asserted-by":"publisher","first-page":"985","DOI":"10.20892\/j.issn.2095-3941.2023.0333","volume":"20","author":"S Zhang","year":"2024","unstructured":"Zhang S, Yang R, Ouyang Y, Shen Y, Hu L, Xu C. Cancer stem cells: a target for overcoming therapeutic resistance and relapse. Cancer Biology Med. 2024;20(12):985.","journal-title":"Cancer Biology Med"},{"issue":"8","key":"15925_CR40","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1073\/pnas.90.8.3539","volume":"90","author":"G Dranoff","year":"1993","unstructured":"Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci. 1993;90(8):3539\u201343.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"15925_CR41","doi-asserted-by":"publisher","first-page":"e1025","DOI":"10.1002\/imed.1025","volume":"1","author":"RJ Soiffer","year":"2021","unstructured":"Soiffer RJ, Kooshesh KA, Ho V. Whole tumor cell vaccines engineered to secrete GM-CSF (GVAX). ImmunoMedicine. 2021;1(1):e1025.","journal-title":"ImmunoMedicine"},{"issue":"9","key":"15925_CR42","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/sj.leu.2404787","volume":"21","author":"J Kessler","year":"2007","unstructured":"Kessler J, Melief C. Identification of T-cell epitopes for cancer immunotherapy. Leukemia. 2007;21(9):1859\u201374.","journal-title":"Leukemia"},{"issue":"1","key":"15925_CR43","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","volume":"15","author":"J Liu","year":"2022","unstructured":"Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15(1):28.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"15925_CR44","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Therapy. 2023;8(1):450.","journal-title":"Signal Transduct Target Therapy"},{"issue":"10","key":"15925_CR45","first-page":"1870","volume":"7","author":"F Zhao","year":"2015","unstructured":"Zhao F, He X, Sun J, Wu D, Pan M, Li M, et al. Cancer stem cell vaccine expressing ESAT-6-gpi and IL-21 inhibits melanoma growth and metastases. Am J Translational Res. 2015;7(10):1870.","journal-title":"Am J Translational Res"},{"issue":"1\u20132","key":"15925_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cellimm.2013.07.018","volume":"284","author":"X Liu","year":"2013","unstructured":"Liu X, Hu J, Cao W, Qu H, Wang Y, Ma Z, et al. Effects of two different immunotherapies on triple negative breast cancer in animal model. Cell Immunol. 2013;284(1\u20132):111\u20138.","journal-title":"Cell Immunol"},{"key":"15925_CR47","doi-asserted-by":"publisher","first-page":"106850","DOI":"10.1016\/j.intimp.2020.106850","volume":"88","author":"M Guo","year":"2020","unstructured":"Guo M, Luo B, Pan M, Li M, Xu H, Zhao F, et al. Colorectal cancer stem cell vaccine with high expression of MUC1 serves as a novel prophylactic vaccine for colorectal cancer. Int Immunopharmacol. 2020;88:106850.","journal-title":"Int Immunopharmacol"},{"key":"15925_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-015-0211-1","volume":"6","author":"Y-t Zhu","year":"2015","unstructured":"Zhu Y-t, Pang S-y, Lei C-y, Luo Y, Chu Q-j. Tan W-l. Development of a therapy against metastatic bladder cancer using an interleukin-2 surface-modified MB49 bladder cancer stem cells vaccine. Stem Cell Res Ther. 2015;6:1\u201310.","journal-title":"Stem Cell Res Ther"},{"key":"15925_CR49","doi-asserted-by":"crossref","unstructured":"Wu D, Yu X, Wang J, Hui X, Zhang Y, Cai Y et al. Ovarian cancer stem cells with high ROR1 expression serve as a new prophylactic vaccine for ovarian cancer. Journal of immunology research. 2019;2019.","DOI":"10.1155\/2019\/9394615"},{"issue":"2","key":"15925_CR50","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/vaccines8020147","volume":"8","author":"A G\u0105bka-Buszek","year":"2020","unstructured":"G\u0105bka-Buszek A, Kwiatkowska-Borowczyk E, Jankowski J, Koz\u0142owska AK, Mackiewicz A. Novel genetic melanoma vaccines based on induced pluripotent stem cells or melanosphere-derived stem-like cells display high efficacy in a murine tumor rejection model. Vaccines. 2020;8(2):147.","journal-title":"Vaccines"},{"key":"15925_CR51","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.intimp.2017.09.019","volume":"52","author":"F Zhao","year":"2017","unstructured":"Zhao F, Zhang R, Wang J, Wu D, Pan M, Li M, et al. Effective tumor immunity to melanoma mediated by B16F10 cancer stem cell vaccine. Int Immunopharmacol. 2017;52:238\u201344.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"15925_CR52","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","volume":"22","author":"MY Choi","year":"2018","unstructured":"Choi MY, Widhopf GF, Ghia EM, Kidwell RL, Hasan MK, Yu J, et al. Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia. Cell Stem Cell. 2018;22(6):951\u20139. e3.","journal-title":"Cell Stem Cell"},{"issue":"18","key":"15925_CR53","doi-asserted-by":"publisher","first-page":"18960","DOI":"10.1002\/cam4.6520","volume":"12","author":"A Izadpanah","year":"2023","unstructured":"Izadpanah A, Mohammadkhani N, Masoudnia M, Ghasemzad M, Saeedian A, Mehdizadeh H, et al. Update on immune-based therapy strategies targeting cancer stem cells. Cancer Med. 2023;12(18):18960\u201380.","journal-title":"Cancer Med"},{"issue":"17","key":"15925_CR54","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3390\/cells12172159","volume":"12","author":"M Kaczmarek","year":"2023","unstructured":"Kaczmarek M, Pozna\u0144ska J, Fechner F, Michalska N, Paszkowska S, Napiera\u0142a A, et al. Cancer vaccine therapeutics: limitations and effectiveness\u2014A literature review. Cells. 2023;12(17):2159.","journal-title":"Cells"},{"key":"15925_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-021-01448-1","volume":"23","author":"JC Lal","year":"2021","unstructured":"Lal JC, Townsend MG, Mehta AK, Oliwa M, Miller E, Sotayo A, et al. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer. Breast Cancer Res. 2021;23:1\u201324.","journal-title":"Breast Cancer Res"},{"issue":"11","key":"15925_CR56","doi-asserted-by":"publisher","first-page":"e0165817","DOI":"10.1371\/journal.pone.0165817","volume":"11","author":"AC Gregorio","year":"2016","unstructured":"Gregorio AC, Fonseca NA, Moura V, Lacerda M, Figueiredo P, Simoes S, et al. Inoculated cell density as a determinant factor of the growth dynamics and metastatic efficiency of a breast cancer murine model. PLoS ONE. 2016;11(11):e0165817.","journal-title":"PLoS ONE"},{"key":"15925_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1741-7015-10-172","volume":"10","author":"Q Sun","year":"2012","unstructured":"Sun Q, Zhong Y, Wu F, Zhou C, Wang D, Ma W, et al. Immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice. BMC Med. 2012;10:1\u201315.","journal-title":"BMC Med"},{"issue":"4","key":"15925_CR58","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/cgt.2016.80","volume":"24","author":"C Sakamoto","year":"2017","unstructured":"Sakamoto C, Kohara H, Inoue H, Narusawa M, Ogawa Y, Hirose-Yotsuya L, et al. Therapeutic vaccination based on side population cells transduced by the granulocyte\u2013macrophage colony-stimulating factor gene elicits potent antitumor immunity. Cancer Gene Ther. 2017;24(4):165\u201374.","journal-title":"Cancer Gene Ther"},{"issue":"8","key":"15925_CR59","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.4049\/jimmunol.0803989","volume":"182","author":"C Lohmann","year":"2009","unstructured":"Lohmann C, Muschaweckh A, Kirschnek S, Jennen L, Wagner H, H\u00e4cker G. Induction of tumor cell apoptosis or necrosis by conditional expression of cell death proteins: analysis of cell death pathways and in vitro immune stimulatory potential. J Immunol. 2009;182(8):4538\u201346.","journal-title":"J Immunol"},{"issue":"02","key":"15925_CR60","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.cpt.2022.12.002","volume":"1","author":"H Ahmed","year":"2023","unstructured":"Ahmed H, Mahmud AR, Faijanur-Rob-Siddiquee M, Shahriar A, Biswas P, Shimul MEK, et al. Role of T cells in cancer immunotherapy: Opportunities and challenges. Cancer pathogenesis therapy. 2023;1(02):116\u201326.","journal-title":"Cancer pathogenesis therapy"},{"issue":"1","key":"15925_CR61","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev.pathmechdis.3.121806.151456","volume":"3","author":"KL Rock","year":"2008","unstructured":"Rock KL, Kono H. The inflammatory response to cell death. Annu Rev Pathol Mech Dis. 2008;3(1):99\u2013126.","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"2","key":"15925_CR62","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.2277","volume":"214","author":"T Wynn","year":"2008","unstructured":"Wynn T. Cellular and molecular mechanisms of fibrosis. J Pathology: J Pathological Soc Great Br Irel. 2008;214(2):199\u2013210.","journal-title":"J Pathology: J Pathological Soc Great Br Irel"},{"key":"15925_CR63","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.matbio.2017.11.010","volume":"68","author":"M Mack","year":"2018","unstructured":"Mack M. Inflammation and fibrosis. Matrix Biol. 2018;68:106\u201321.","journal-title":"Matrix Biol"},{"issue":"48","key":"15925_CR64","doi-asserted-by":"publisher","first-page":"17188","DOI":"10.1073\/pnas.1419554111","volume":"111","author":"T Alkasalias","year":"2014","unstructured":"Alkasalias T, Flaberg E, Kashuba V, Alexeyenko A, Pavlova T, Savchenko A, et al. Inhibition of tumor cell proliferation and motility by fibroblasts is both contact and soluble factor dependent. Proc Natl Acad Sci. 2014;111(48):17188\u201393.","journal-title":"Proc Natl Acad Sci"},{"key":"15925_CR65","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.trsl.2019.02.006","volume":"209","author":"C Chandler","year":"2019","unstructured":"Chandler C, Liu T, Buckanovich R, Coffman LG. The double edge sword of fibrosis in cancer. Translational Res. 2019;209:55\u201367.","journal-title":"Translational Res"},{"issue":"1","key":"15925_CR66","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ccell.2023.12.011","volume":"42","author":"ET Goddard","year":"2024","unstructured":"Goddard ET, Linde MH, Srivastava S, Klug G, Shabaneh TB, Iannone S, et al. Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. Cancer Cell. 2024;42(1):119\u201334. e12.","journal-title":"Cancer Cell"},{"issue":"11","key":"15925_CR67","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3390\/biomedicines9111613","volume":"9","author":"H Drescher","year":"2021","unstructured":"Drescher H, Weiskirchen S, Weiskirchen R. Flow cytometry: A blessing and a curse. Biomedicines. 2021;9(11):1613.","journal-title":"Biomedicines"},{"issue":"1","key":"15925_CR68","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/cpim.40","volume":"120","author":"KM McKinnon","year":"2018","unstructured":"McKinnon KM. Flow cytometry: an overview. Curr protocols Immunol. 2018;120(1):5. -5.1. 11.","journal-title":"Curr protocols Immunol"},{"key":"15925_CR69","doi-asserted-by":"crossref","unstructured":"Im K, Mareninov S, Diaz MFP, Yong WH. An introduction to performing immunofluorescence staining: Springer; 2019.","DOI":"10.1007\/978-1-4939-8935-5_26"},{"issue":"9","key":"15925_CR70","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.3390\/cells10092361","volume":"10","author":"C Galassi","year":"2021","unstructured":"Galassi C, Musella M, Manduca N, Maccafeo E, Sistigu A. The immune privilege of cancer stem cells: a key to understanding tumor immune escape and therapy failure. Cells. 2021;10(9):2361.","journal-title":"Cells"},{"issue":"17","key":"15925_CR71","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323\u201337.","journal-title":"Clin Cancer Res"},{"key":"15925_CR72","first-page":"86","volume":"175","author":"J Zhang","year":"2015","unstructured":"Zhang J, Tao A. Antigenicity, immunogenicity, allergenicity. Allergy Bioinf. 2015;175:86.","journal-title":"Allergy Bioinf"},{"issue":"1","key":"15925_CR73","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4103\/0974-777X.77299","volume":"3","author":"AS Clem","year":"2011","unstructured":"Clem AS. Fundamentals of vaccine immunology. J global Infect Dis. 2011;3(1):73.","journal-title":"J global Infect Dis"},{"issue":"7","key":"15925_CR74","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1111\/jcmm.16401","volume":"25","author":"M Naseri","year":"2021","unstructured":"Naseri M, Z\u00f6ller M, Hadjati J, Ghods R, Ranaei Pirmardan E, Kiani J, et al. Dendritic cells loaded with exosomes derived from cancer stem cell-enriched spheroids as a potential immunotherapeutic option. J Cell Mol Med. 2021;25(7):3312\u201326.","journal-title":"J Cell Mol Med"},{"issue":"10","key":"15925_CR75","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3390\/biom10101431","volume":"10","author":"A Negroni","year":"2020","unstructured":"Negroni A, Colantoni E, Cucchiara S, Stronati L. Necroptosis in intestinal inflammation and cancer: new concepts and therapeutic perspectives. Biomolecules. 2020;10(10):1431.","journal-title":"Biomolecules"},{"issue":"1","key":"15925_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-1029-8","volume":"18","author":"Y Gong","year":"2019","unstructured":"Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K, et al. The role of necroptosis in cancer biology and therapy. Mol Cancer. 2019;18(1):1\u201317.","journal-title":"Mol Cancer"},{"issue":"1","key":"15925_CR77","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/imr.12583","volume":"280","author":"O Krysko","year":"2017","unstructured":"Krysko O, Aaes TL, Kagan VE, D\u2019Herde K, Bachert C, Leybaert L, et al. Necroptotic cell death in anti-cancer therapy. Immunol Rev. 2017;280(1):207\u201319.","journal-title":"Immunol Rev"},{"issue":"36","key":"15925_CR78","doi-asserted-by":"publisher","first-page":"eaaw2004","DOI":"10.1126\/sciimmunol.aaw2004","volume":"4","author":"AG Snyder","year":"2019","unstructured":"Snyder AG, Hubbard NW, Messmer MN, Kofman SB, Hagan CE, Orozco SL, et al. Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity. Sci Immunol. 2019;4(36):eaaw2004.","journal-title":"Sci Immunol"},{"issue":"2","key":"15925_CR79","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.bbcan.2016.03.003","volume":"1865","author":"D Chen","year":"2016","unstructured":"Chen D, Yu J, Zhang L. Necroptosis: an alternative cell death program defending against cancer. Biochim et Biophys Acta (BBA)-Reviews Cancer. 2016;1865(2):228\u201336.","journal-title":"Biochim et Biophys Acta (BBA)-Reviews Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15925-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15925-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15925-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:05:34Z","timestamp":1781643934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15925-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,29]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15925"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15925-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,29]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Research Ethics Committee of Iran University of Medical Sciences approved the project entitled \u201cThe Effect of a Cancer Stem Cell\u2013Based Therapeutic Vaccine on Tumorigenesis in a Colorectal Cancer Mouse Model\u201d under ethical approval code IR.IUMS.REC.1398.954. All procedures performed in this study were conducted in accordance with the ethical standards of the institution at which the study was carried out.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"614"}}